Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by CalgaryATEon May 19, 2021 1:17am
229 Views
Post# 33228117

RE:RE:three-cornered amalgamation transaction?

RE:RE:three-cornered amalgamation transaction?
MrMugsy wrote: The way I read that Nick was ... you have ATE and you have AH and then you add a new subsiduary to ATE where the patents will get transferred.  Upon transfer completion, you eliminate AH.

That's what I thought they meant - just for the "transaction" is it 3-cornered.

Anyone ?


If you go to sedar and open "Other material contracts - English" from May 14, 2021, you can go to Article 2 - Business Combination (page 10 of the document and page 14 of the pdf) for a very descriptive (and extremely dense legalese). 

My interpretation is you're correct (but who knows, perhaps I'm wrong):

Holdings votes on amalgamation.

If Holdings approves amalgamation, Holdings merges with a wholly owned subsidiary of Therapetuics (Subco - 2831094 Ontario Inc).  This Holdings/Subco combined company is combined (amlagamated) and now called Amalco.

Each Holdings share is exchanged for 0.2581 shares of Therapeutics (there's about 22.6 million shares of Holdings, so that's where they get the 5.87 million shares of Therapeutics to owners of Holdings).

Then all Holdings shares are cancelled.

Therapeutics than gets 1 share of Amalco for every share of Subco, then all shares of Subco are cancelled.

So Therapeutics ends up owning 100% of Amalco (this wholly owned subsidiary has all the stuff Holdings had, patents, IP, etc.) while Holdings shareholders get those 5.87 million shares of Therapeutics (already news released).

Then there's some stuff on taxes and on what happens for Holdings shareholders who vote against amalgamation and then a whole bunch of other stuff (50+ pages of legalese).

Might do a post tomorrow on shareholders of Holdings and the Holdings vote on amalgamation.
<< Previous
Bullboard Posts
Next >>